HomeInsightsStock Comparison

Alembic Pharmaceuticals Ltd vs Supriya Lifescience Ltd Stock Comparison

Alembic Pharmaceuticals Ltd vs Supriya Lifescience Ltd Stock Comparison

Last Updated on: May 18, 2025

Key Highlights

  • The Latest Trading Price of Alembic Pharmaceuticals Ltd is ₹ 913.75 as of 16 May 15:30.
  • The P/E Ratio of Alembic Pharmaceuticals Ltd changed from 12.1 on March 2020 to 31.4 on March 2024 . This represents a CAGR of 21.01% over 5 yearsThe P/E Ratio of Supriya Lifescience Ltd changed from 0 on March 2020 to 0 on March 2024 . This represents a CAGR of 0.0% over 5 years.
  • The Market Cap of Alembic Pharmaceuticals Ltd changed from ₹ 10059 crore on March 2020 to ₹ 19309 crore on March 2024 . This represents a CAGR of 13.93% over 5 yearsThe Market Cap of Supriya Lifescience Ltd changed from ₹ 0 crore on March 2020 to ₹ 0 crore on March 2024 . This represents a CAGR of 0.0% over 5 years.
  • The revenue of Alembic Pharmaceuticals Ltd for the Mar '25 is ₹ 1783 crore as compare to the Dec '24 revenue of ₹ 1702 crore. This represent the growth of 4.77% The revenue of Supriya Lifescience Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 revenue of ₹ 0 crore. This represent the decline of 0%.
  • The ebitda of Alembic Pharmaceuticals Ltd for the Mar '25 is ₹ 285.46 crore as compare to the Dec '24 ebitda of ₹ 270.08 crore. This represent the growth of 5.69% The ebitda of Supriya Lifescience Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 ebitda of ₹ 0 crore. This represent the decline of 0%.
  • The net profit of Alembic Pharmaceuticals Ltd changed from ₹ 120.6 crore to ₹ 156.63 crore over 8 quarters. This represents a CAGR of 13.96% The net profit of Supriya Lifescience Ltd changed from ₹ 0 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of 0.0% .
  • The Dividend Payout of Alembic Pharmaceuticals Ltd changed from 19.45 % on March 2020 to 32.44 % on March 2024 . This represents a CAGR of 10.77% over 5 yearsThe Dividend Payout of Supriya Lifescience Ltd changed from 19.96 % on March 2020 to 5.41 % on March 2024 . This represents a CAGR of -22.98% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Alembic Pharmaceuticals Ltd

  • Alembic Pharmaceuticals manufactures and markets generic pharmaceutical products all over the world.
  • The company's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. The company is one of the leaders in branded generics in India. Alembic Pharmaceuticals Ltd was incorporated on June 16, 2010 as a wholly owned subsidiary of Alembic Ltd. The company is engaged in pharmaceuticals business.
  • As per the scheme of arrangement, the 'Pharmaceutical Undertaking' of the Alembic Ltd was demerged and transferred to the company with effect from appointed date, April 1, 2010. In April 15, 2011, the company ceased to be a subsidiary of Alembic Ltd consequent to the allotment of 13,35,15,914 equity shares of Rs 2 each to the shareholders of Alembic Ltd as per the scheme of arrangement.

About Supriya Lifescience Ltd

  • Supriya Lifescience Limited was initially constituted on October 29, 1985, as a 'Partnership Firm under the name M/s Supriya Chemicals'.
  • The Partnership Firm was last re-constituted pursuant to a Partnership Deed dated November 30, 2007.
  • Upon the conversion of M/s Supriya Chemicals' the Partnership Firm into a Public Limited Company, the Company got incorporated as Supriya Lifescience Limited' vide certified on March 26, 2008 by the Registrar of Companies, Mumbai. The Company commenced operations in April, 2008.
  • It is engaged in manufacturing and export of active pharmaceutical ingredients (APIs).
  • The company is one of the key Indian manufacturers and suppliers of active pharmaceuticals ingredients,with a focus on research and development.

Alembic Pharmaceuticals Ltd News Hub

News

Alembic Pharmaceuticals receives USFDA approval for Rivaroxaban Tablets

Alembic Pharmaceuticals (Alembic) today announced that it has received final approval from...

Read more

15 May 2025 14:14

News

Alembic Pharma rises on USFDA approval for Rivaroxaban Tablets

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD)...

Read more

15 May 2025 16:36

News

Board of Alembic Pharmaceuticals recommends final dividend

Alembic Pharmaceuticals announced that the Board of Directors of the Company at its meetin...

Read more

06 May 2025 14:39

News

Alembic Pharma slips after Q4 PAT drops 12% YoY to Rs 157 cr

Revenue from operations grew 16.66% year on year (YoY) to Rs 1,769.64 crore in the quarter...

Read more

06 May 2025 15:26

News

Alembic Pharmaceuticals receives USFDA final approval for Ticagrelor Tablets

Alembic Pharmaceuticals (Alembic) today announced that it has received final approval from...

Read more

02 May 2025 14:55

News

Alembic Pharma gains after receiving EIR from USFDA for Panelav facility

The company announced in an exchange filing that the EIR pertains to an inspection conduct...

Read more

30 Apr 2025 13:17

Supriya Lifescience Ltd News Hub

News

Board of Supriya Lifescience appoints company secretary and compliance officer

The Board of Supriya Lifescience at its meeting held on 10 March 2025 has approved the app...

Read more

10 Mar 2025 15:37

News

Supriya Lifesciences to hold board meeting

Supriya Lifesciences will hold a meeting of the Board of Directors of the Company on 10 Ma...

Read more

06 Mar 2025 09:34

News

Supriya Lifesciences declare Quarterly Result

Supriya Lifesciences will hold a meeting of the Board of Directors of the Company on 24 Ja...

Read more

17 Jan 2025 11:05

News

Supriya Lifescience inaugurates new API production block at Lote Parshuram site

Supriya Lifescience  inaugurated its new multipurpose Active Pharmaceutical Ingredients (A...

Read more

17 Dec 2024 16:57

News

Supriya Life gains after bagging approval from ANVISA for Esketamine Hydrochloride

Esketamine hydrochloride is a vital drug to be used for treating mental illness and is lik...

Read more

09 Dec 2024 15:58

News

Supriya Lifesciences to announce Quarterly Result

Supriya Lifesciences will hold a meeting of the Board of Directors of the Company on 28 Oc...

Read more

21 Oct 2024 15:38

SWOT Analysis Of Alembic Pharmaceuticals Ltd

Strength

1

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Supriya Lifescience Ltd

Strength

0

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Alembic Pharmaceuticals Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Supriya Lifescience Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Alembic Pharmaceuticals Ltd and Supriya Lifescience Ltd

Which company has a larger market capitalization, Alembic Pharmaceuticals Ltd or Supriya Lifescience Ltd?

Market cap of Alembic Pharmaceuticals Ltd is 17,960 Cr while Market cap of Supriya Lifescience Ltd is 5,607 Cr

What are the key factors driving the stock performance of Alembic Pharmaceuticals Ltd and Supriya Lifescience Ltd?

The stock performance of Alembic Pharmaceuticals Ltd and Supriya Lifescience Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Alembic Pharmaceuticals Ltd and Supriya Lifescience Ltd?

As of May 18, 2025, the Alembic Pharmaceuticals Ltd stock price is INR ₹913.75. On the other hand, Supriya Lifescience Ltd stock price is INR ₹696.75.

How do dividend payouts of Alembic Pharmaceuticals Ltd and Supriya Lifescience Ltd compare?

To compare the dividend payouts of Alembic Pharmaceuticals Ltd and Supriya Lifescience Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions